Concurrence of systemic lupus erythematosus and psoriatic arthritis: literature data and a case report
https://doi.org/10.14412/1996-7012-2018-4-123-128
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune systemic inflammatory disease with various clinical manifestations. There are descriptions of overlap syndromes when the signs of several systemic connective tissue diseases, such as rheumatoid arthritis, systemic sclerosis, dermatomyositis, and SjЪgren's syndrome, are simultaneously recorded. Psoriasis belongs to chronic skin diseases of multifactorial genesis, which is determined by genetic, immunological, and environmental factors. About one out of three patients with psoriasis develops psoriatic arthritis (PsA), an inflammatory joint injury. The concurrence of SLE and PsA is rare; there are very few reports on such clinical situations. A special variant of SLE, such as subacute cutaneous lupus erythematosus, can mimic skin lesions in psoriasis, which causes diagnostic difficulties.
The paper gives the data available in the literature on the concurrence of SLE, PsA, and psoriasis. It discusses the specific features of the differential diagnosis of the concurrence of the two nosological entities and its treatment policy. The authors give their own clinical case of the concurrence of SLE and PSA, as well as several descriptions of such cases available in the literature.
About the Authors
E. M. Agafonova
V.A.Nasonova Research Institute of Rheumatology.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
N. G. Klyukvina
V.A.Nasonova Research Institute of Rheumatology.
Russian Federation
Russian Federation
Natalia Gennadyevna Klyukvina.
34A, Kashirskoe Shosse, Moscow 115522.
M. M. Urumova
V.A.Nasonova Research Institute of Rheumatology.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
References
1. Nasonov EL, editor. Klinicheskie rekomendatsii po revmatologii [Clinical guidelines for rheumatology]. Moscow: GEOTAR-Media; 2010. P. 429-81.
2. Klyukvina NG, Nasonov EL. The clinical and laboratory manifestations of systemic lupus erythematosus. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2012;6(4):40-8. (In Russ.). doi: 10.14412/1996-7012-2012-761
3. Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002 Dec;16(5):847-58.
4. Lorber M, Gershwin ME, Shoenfeld Y. The coexistence of systemic lupus erythematosus with other autoimmune diseases: the kaleidoscope of autoimmunity. Semin Arthritis Rheum. 1994 Oct;24(2):105-13.
5. Avriel A, Zeller L, Flusser D, et al. Coexistence of psoriatic arthritis and systemic lupus erythematosus. Isr Med Assoc J. 2007 Jan;9(1):48-9.
6. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013 Nov;69(5):729-735. doi: 10.1016/j.jaad.2013.07.023. Epub 2013 Aug 24.
7. Hamilton MP, Ntais D, Griffiths CE, Davies LM; Identification and Management of Psoriasis-Associated ComorbidiTy (IMPACT) Team. Psoriasis treatment and management - a systematic review of full economic evaluations. Br J Dermatol. 2015 Mar;172(3):574-83. doi: 10.1111/bjd.13486. Epub 2015 Feb 11.
8. Wohl Y, Brenner S. Cutaneous LE or psoriasis: a tricky differential diagnosis. Lupus, 2004: 13: 72-74.
9. Reich K, Krü ger K, Mö ssner R, et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009 May;160(5):1040-7. doi: 10.1111/j.1365-2133.2008.09023.x. Epub 2009 Feb 4.
10. Chamurlieva MN, Loginova EYu, Korotaeva TV. Detection rates of psoriatic arthritis in patients with psoriasis in a dermatology and rheumatology clinic. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(4):47–50. (In Russ.). doi: 10.14412/1996-7012-2016-4-47-50
11. Badokin VV, Troshkina IA. Clinical heterogeneity of early psoriatic arthritis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(4):51–56. (In Russ.). doi: 10.14412/1996-7012-2016-4-51-56
12. Dubois EL. Lupus erythematosus. (2nd ed). Los Angeles: University of Southern California Press; 1974. P. 559-64.
13. Tumarkin BM, Menshikova AK, Glavinskaya TA. Some data on clinical pattern and course of discoid lupus erythematosus and of psoriasis when they occur simultaneously in patients. Vestn Dermatol Venerol. 1971 Feb;45(2):43-7.
14. Zalla MJ, Muller SA. The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Acta Derm Venereol Suppl (Stockh). 1996;195:1-15.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725.
16. Kulick KB, Mogavero H, Provost TT, Reichlin M. Serologic studies in patients with lupus erythematosus and psoriasis. J Am Acad Dermatol. 1983 May;8(5):631-4.
17. Nasonov EL, Karateev DE, Chichasova NV. EULAR recommendations for the treatment of rheumatoid arthritis – 2013: general characteristics and disputable problems. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(6):609-22. (In Russ.). Doi: 10.14412/1995-4484-2013-609-22
18. Bonilla E, Shadakshari A, Perl A. Association of psoriasis and psoriatic arthritis with systemic lupus erythematosus. Rheumatol Orthop Med. 2016;1(1):1-3.
19. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-73.
20. Millns JL, Muller SA. The coexistence of psoriasis and lupus erythematosus. An analysis of 27 cases. Arch Dermatol. 1980;116:658-663.
21. Agababova ER, Badokin VV, Erdes ShF, et al. Development and testing of diagnostic criteria for psoriatic arthritis. Terapevticheskii arkhiv. 1998;(12):117-21. (In Russ.)
22. Petri M, Orbai A, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8): 2677-86. doi: 10.1002/art.34473.
23. Sezgin AO, Turk BG, Ertam I, et al. A case of psoriasis complicated with systemic lupus erythematosus. J Turk Acad Dermatol. 2010;4(4):04403c.
24. Toll A, Campo-Pisa P, Gonzalez-Castro I, et al. Subacute SLE associated with cinnarizine and thietylperasine therapy. Lupus. 1998;7(5):364-6.
25. Nalbandian A1, Crispin JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol. 2009 Aug;157(2):209-15. doi: 10.1111/j.1365-2249.2009.03944.x.
26. Hsu HC, Yang P, Wang J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol. 2008 Feb;9(2): 166-75. Epub 2007 Dec 23.
27. Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014 May;66(5):1272-81. doi: 10.1002/art.38376.
28. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28.
29. Nasonov EL. Treatment of rheumatoid arthritis 2017. Klinicheskaya farmakologiya i terapiya. 2017;26(1):4-10. (In Russ.).
30. Van Der Fits L, Van Der Wel LI, Laman JD, et al. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol. 2004 Jan; 122(1):51-60.
31. Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferonalpha. Br J Dermatol. 1991 Nov;125(5):463-5.
32. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006 Sep; 54(9):2951-62.
33. Obermoser G, Pascual V. The interferonalpha signature of systemic lupus erythematosus. Lupus. 2010 Aug;19(9):1012-9. doi: 10.1177/0961203310371161.
34. Shibata S, Tada Y, Kanda N, et al. Possible roles of IL-27 in the pathogenesis of psoriasis. J Invest Dermatol. 2010 Apr;130(4): 1034-9. doi: 10.1038/jid.2009.349. Epub 2009 Nov 19.
35. Kido M, Takeuchi S, Sugiyama N, et al. T cell-specific overexpression of interleukin-27 receptor α subunit (WSX-1) prevents spontaneous skin inflammation in MRL/lpr mice. Br J Dermatol. 2011 Jun;164(6):1214-20. doi: 10.1111/j.1365-2133.2011.10244.x. Epub 2011 May 17.
36. Tojo G, Fujimura T, Kambayashi Y, Aiba S. Systemic lupus erythematosus accompanied by psoriasis induces IL-27-Producing cells in both affected areas of the skin. Case Rep Dermatol. 2012 May;4(2):181-5. doi: 10.1159/000342803. Epub 2012 Aug 30.
37. Клюквина НГ. Системная красная волчанка у мужчин. Русский медицинский журнал. 2014;22(28):2012-4. [Klyukvina NG. Systemic lupus erythematosus in men. Russkii meditsinskii zhurnal. 2014;22(28):2012-4. (In Russ.)].
38. Korotaeva TV, Korsakova YuL. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(1):60-9. (In Russ.). doi: 10.14412/1995-4484-2018-60-69
39. Wielosz E, Majdan M, Zychowska I, Jeleniewicz R. Coexistence of five autoimmune diseases: diagnostic and therapeutic difficulties. Case Rep Dermatol. 2012 May; 4(2):181-5. doi: 10.1159/000342803. Epub 2012 Aug 30.
Review
For citations:
Agafonova EM, Klyukvina NG, Urumova MM. Concurrence of systemic lupus erythematosus and psoriatic arthritis: literature data and a case report. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2018;12(4):123-128. (In Russ.) https://doi.org/10.14412/1996-7012-2018-4-123-128
Views:
4834
Email this article 